Common questions
PT-141 Questions, Answered From the Record
Direct, cited answers — with the approved-versus-off-label line drawn in each one.
Can you get PT-141 through telehealth?
Where bremelanotide is an approved prescription drug, access generally runs through licensed prescribing, and remote evaluation has been described for sexual-medicine care: a review documents telemedicine workflows for sexual-medicine patients, and international data tracks its adoption [8][14]. This site does not arrange, facilitate, or advise on obtaining PT-141 — it appraises the evidence. The approved drug is one thing; the unregulated research-chemical form is another, with no oversight [7].
What is PT-141?
PT-141, a synthetic alpha-MSH analogue, is an agonist at melanocortin receptors (MC3R/MC4R) expressed primarily in the central nervous system [1]. Systemic administration produced penile erections in rats and nonhuman primates and activated hypothalamic neurons, and produced rapid, dose-dependent erectile activity in men with erectile dysfunction [1]. It is approved as bremelanotide only for premenopausal HSDD [7].
What is PT-141 peptide?
PT-141 peptide is a cyclic heptapeptide — a ring of seven amino acids — that is a lactam-bridged analogue of alpha-MSH, the body's own melanocortin signal [1]. It targets central MC3R/MC4R receptors rather than acting on blood vessels, which distinguishes it mechanistically from PDE-5 inhibitors [1]. Its cyclic structure gives it more stability than linear melanocortin peptides [1].
What does the PT-141 peptide do?
PT-141, a synthetic alpha-MSH analogue, is an agonist at melanocortin receptors (MC3R/MC4R) expressed primarily in the CNS [1]. In animals it produced erections and activated hypothalamic neurons; in trials of premenopausal women with HSDD it improved sexual desire and reduced desire-related distress versus placebo [1][3]. It works on the brain's motivation circuitry, not on peripheral blood flow [1].
What is PT-141 used for?
Its single approved use is acquired, generalized HSDD in premenopausal women, as bremelanotide injection [7]. Every other use — men, postmenopausal women, "performance" — is off-label or research-stage, not approved [7]. Mechanistically it agonizes central MC3R/MC4R receptors tied to sexual desire [1]. This site reports the approved evidence and the off-label evidence as separate things.
Is PT-141 the same as bremelanotide?
Yes — PT-141 is the development code and bremelanotide is the international nonproprietary name (INN) for the same melanocortin MC3R/MC4R agonist [1][7]. There is a practical distinction worth keeping: "bremelanotide" usually refers to the FDA-approved pharmaceutical, while "PT-141" is also used for an unregulated research-chemical form with no oversight of identity or purity [7].
What is bremelanotide?
Bremelanotide is the INN for PT-141, a synthetic alpha-MSH analogue that agonizes central melanocortin receptors (MC3R/MC4R) [1]. It was approved in 2019 for premenopausal HSDD at 1.75 mg subcutaneous as needed [7]. It acts in the brain's sexual-motivation circuitry rather than on peripheral blood flow, distinguishing it from PDE-5 inhibitors [1].
How does PT-141 work?
It agonizes melanocortin MC4R (and MC3R) receptors in hypothalamic circuits such as the medial preoptic area, engaging dopaminergic pathways for appetitive sexual behavior [1]. Human fMRI shows it raises desire and alters brain processing of erotic cues for up to 24 hours, and in vitro work shows it does not relax peripheral vaginal tissue — together confirming a central, not vascular, mechanism [5][13].
What receptors does PT-141 act on?
PT-141 acts chiefly on the melanocortin 4 receptor (MC4R) and secondarily on the melanocortin 3 receptor (MC3R), both concentrated in central-nervous-system circuits governing sexual motivation [1]. It also activates peripheral MC1R with repeated dosing, which is why hyperpigmentation can occur [7]. Its central MC4R activity is the basis of its approved effect [1].
Does PT-141 work through the brain or through blood flow?
Through the brain. PT-141 acts on central MC4R/MC3R receptors in the hypothalamus, not on vascular smooth muscle [1]. In vitro, bremelanotide (1 µM) failed to relax rabbit vaginal tissue while alpha-MSH relaxed it — direct evidence against a peripheral blood-flow mechanism [13]. This is the core difference between PT-141 and PDE-5 inhibitors, which act on blood flow.
What is a melanocortin receptor agonist?
A melanocortin receptor agonist is a molecule that activates one or more of the five melanocortin receptors (MC1R–MC5R), which normally respond to melanocortin peptides like alpha-MSH [1]. PT-141 is one such agonist, targeting the central MC3R and MC4R subtypes tied to sexual desire and appetite, with some peripheral MC1R activity that affects pigmentation [1][7].
Does PT-141 increase testosterone?
No. PT-141 does not act through the hypothalamic-pituitary-gonadal axis and does not directly raise testosterone — this is a common misconception [1]. Its mechanism is central melanocortin (MC3R/MC4R) agonism affecting sexual-motivation circuitry, not hormonal stimulation of the testes [1]. Claims that it boosts testosterone describe a drug this is not.
How is PT-141 different from PDE-5 inhibitors?
PDE-5 inhibitors act peripherally on vascular smooth muscle to improve erectile blood flow; PT-141 acts centrally on brain melanocortin receptors that govern sexual desire [1]. The in vitro evidence is direct — bremelanotide did not relax peripheral tissue that alpha-MSH relaxed [13]. Practically, one targets blood flow and the other targets desire, which is why their effects and side effects differ.
What is the PT-141 dosage?
The approved PT-141 (bremelanotide) dosage is 1.75 mg subcutaneous, as needed, no more than one dose per 24 hours and no more than eight doses per month, per the US prescribing information [7]. Terminal half-life is ~2.7 h (range 1.9–4.0 h) [7]. This is reported as a labeled figure, not as a recommendation for any individual.
How much PT-141 should I take?
This site does not advise any person on how much to take. The published approved figure for bremelanotide is 1.75 mg subcutaneous as needed within a monthly cap of eight doses, for premenopausal women with HSDD [7]. That is a label value reported as evidence; dosing decisions belong to a qualified prescriber, and the research-chemical form has no verified concentration to dose against [7].
How much PT-141 to inject?
The only injection figure with approval-grade evidence is the label's 1.75 mg subcutaneous, as-needed dose for premenopausal HSDD, capped at one per 24 hours and eight per month [7]. This site reports that figure rather than recommending it. Doses outside the label, or for any population outside premenopausal HSDD, are investigational [7].
What is the PT-141 dosage for women?
In female rats, PT-141 selectively stimulated appetitive solicitational sexual behaviors without affecting lordosis, pacing, or general motor activity, indicating central melanocortin systems regulate female sexual desire [2]. The approved human figure for premenopausal women with HSDD is 1.75 mg subcutaneous as needed, reported here as a label value, not a recommendation [7].
How do you reconstitute PT-141?
The approved bremelanotide product ships ready to use, so reconstitution is a question about the unregulated research-chemical form — which has no oversight of identity, purity, or concentration [7]. For that reason this site does not provide reconstitution or preparation instructions; it appraises published evidence rather than offering procedures for an unverified material.
How do you take PT-141?
The approved route is subcutaneous injection, taken as needed at least 45 minutes before anticipated activity, per the label [7]. A beagle-dog PK study confirmed minimal oral absorption, which is why it is injected rather than taken by mouth [10]. This describes the documented administration; it is not an instruction to any reader.
How often can you take PT-141?
The label caps approved use at one dose per 24 hours and no more than eight doses per month [7]. In the 52-week open-label extension (684 women), this as-needed pattern showed no new safety signals and sustained desire improvements, with nausea (40.4%), flushing (20.6%), and headache (12.0%) the most common drug-related events [4]. The monthly cap limits frequency-dependent effects like pigmentation.
What is the approved bremelanotide dose?
Two identical Phase 3 RCTs (RECONNECT, n=1267 premenopausal women with HSDD) supported the approved bremelanotide dose of 1.75 mg subcutaneous as-needed, which produced statistically significant improvement in sexual desire (integrated FSFI-desire +0.35, P<.001) and reduced desire-related distress versus placebo over 24 weeks [3]. The label caps it at one dose per 24 hours and eight per month [7].
How long does PT-141 last?
In plasma, the terminal half-life is about 2.7 hours (range 1.9–4.0 h) after subcutaneous dosing, with Tmax near 0.5–1.0 hour [7]. The behavioral effect outlasts the drug: an fMRI study measured increased sexual desire for up to 24 hours after a single dose [5]. So the molecule clears in hours while the central effect persists longer.